News & Updates

Patients with cirrhosis have a high prevalence of myosteatosis, either alone or in combination with sarcopenia, which can contribute to the development of worse outcomes, reports a study.

New drug applications approved by US FDA as of 1-15 September 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Baseline and dynamic changes in liver stiffness measurement (LSM) show an independent and bidirectional association with the risk of developing liver-related events, suggests a study.

Metabolic dysfunction-associated steatotic liver disease (MASLD) and MASLD with increased alcohol intake (MetALD) may predispose affected individuals to liver and gastrointestinal cancers, as reported in a study.

The investigational L-type amino acid transporter 1 inhibitor nanvuranlat has an acceptable safety profile and is associated with prolonged progression-free survival (PFS) in patients with advanced and refractory biliary tract cancer when used in later-line treatment settings, according to the results of a phase II study.

The extent of liver fibrosis appears to be higher among people living with HIV (PWH) who have metabolic dysfunction-associated steatotic liver disease (MASLD), despite lower NAFLD activity score (NAS) and less pronounced histological drivers of fibrosis, than among their counterparts who have no HIV, according to a study.